Skip to content
Review Open access

Modulation of GABA and Glutamate by Ketamine in Depression: A Systematic Review and Meta-Analysis of Magnetic Resonance Spectroscopy Studies

Sep 2026 · Neuropsychopharmacology · 0 citations · 36 references
Medicine

TL;DR

Rigorous RCTs with standardized protocols, larger sample sizes, uniform dosing, and systematic biomarker investigations are needed to clarify ketamine’s neurochemical mechanism and optimize ketamine’s clinical application in treatment-resistant depression.

Abstract

Disrupted excitation-inhibition (E/I) balance involving GABA and glutamate (Glu) is implicated in the pathophysiology of depression. Ketamine, an NMDA receptor antagonist with rapid antidepressant properties, may modulate this balance, yet proton magnetic resonance spectroscopy (1H-MRS) studies report inconsistent findings regarding the direction, magnitude, and timing of neurochemical effects. Static 1H-MRS metabolite concentrations, however, do not directly index neuronal excitation or inhibition; the E=Glx/Glu and I = GABA framework adopted here, as used commonly in the field, is an assumed convention rather than a validated physiological equivalence. We conducted a systematic review and meta-analysis evaluating ketamine’s influence on GABA, Glu, and Glx levels and their relationship to clinical outcomes in adults with depression. Multiple databases were searched from inception through October 16, 2025; of 1046 identified studies, 11 met inclusion criteria. Included studies demonstrated significant methodological variability across infusion protocols, metabolite selection, MRS acquisition timing, and brain region of interest. Meta-analyses from limited evidence base did not demonstrate statistically significant treatment-related alterations in any metabolite. The anterior cingulate and prefrontal cortices were most frequently examined regions. The quality of included studies was generally good, despite methodological heterogeneity. One RCT found percent reduction in Glx/GABA ratio positively correlated with symptom improvement. Only a few studies examined ketamine blood levels relative to metabolite changes. Current 1H-MRS evidence does not confirm significant ketamine-related neurochemical alterations, likely reflecting methodological heterogeneity in timing, acquisition techniques, and brain regions examined rather than a true absence of effect. E/I balance shows promise as a treatment response predictor. Rigorous RCTs with standardized protocols, larger sample sizes, uniform dosing, and systematic biomarker investigations are needed to clarify ketamine’s neurochemical mechanism and optimize ketamine’s clinical application in treatment-resistant depression.

Read PDF

Similar papers

Review Open access Oct 2026

Magnesium supplementation for anxiety and depression: a systematic review of clinical evidence and mechanistic insights

Magnesium is an essential cofactor in numerous enzymatic reactions regulating neuronal excitability, neurotransmission, and stress response. Deficiency has been linked to affective dysregulation through altered N-methyl-D-aspartate (NMDA) and γ-aminobutyric acid (GABA) signaling, impaired neuroplasticity, and activatio...

Lorenzo Campedelli, Andrea Cicoli, M. Lastretti et al. · 0 citations
Review Sep 2026

Peripheral blood glutamate, glutamine, and GABA in Autism Spectrum disorder: A systematic review and meta-analysis of group differences with an exploratory assessment of diagnostic accuracy.

The diagnostic analyses yielded exploratory marginal pooled estimates of sensitivity and specificity for GABA and Glu and study-specific estimates for the remaining biomarkers, without establishing overall diagnostic accuracy.

Yong-Bo Shi, Xiao-Meng Yin, Jia-Hui Luo et al. · 0 citations
Review Open access Oct 2026

Ketamine in psychiatry: a systematic review of clinical applications, safety considerations, and emerging challenges

Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric appli...

Matthew M. Kinney, Zackary Bowers · 0 citations
Open access Sep 2026

482. Altered GABAb receptor–mediated cortical inhibition in heavy alcohol use: evidence from a pharmaco-TMS study using baclofen

Dose- and group-dependent modulation of GABAbR-mediated cortical inhibition by baclofen is demonstrated, and LICI emerges as a sensitive, non-invasive biomarker of GABAbR function and pharmacodynamic target engagement, with potential utility for stratifying neurobiological heterogeneity and informing the development of...

C. Montemitro, I. Perini, M. Heilig · 0 citations
Review Open access Nov 2026

The efficacy of NMDA receptor antagonists in neuropsychiatric and non-motor symptoms of Parkinson’s disease: a systematic review

ABSTRACT. Parkinson’s disease (PD) involves significant non-motor symptoms (NMS) linked to glutamate dysregulation. Objective: This review evaluates the efficacy of N-methyl-D-aspartate (NMDA) receptor antagonists (memantine and amantadine) for treating NMS. Methods: A search was conducted in the databases PubMed and C...

Jan Arel Solomon Orlino, M. L. Corrales-Joson · 0 citations
Open access Aug 2026

Inhibitory neurotransmission in frontostriatal circuitry: implications for psychomotor and vegetative symptoms in depressive episodes

The findings did not establish that psychomotor or vegetative symptoms were associated with GABA levels or GABAA-receptor availability in the frontostriatal pathways or hypothalamus, and future studies should ideally focus on patients exhibiting more pronounced psychomotor and vegetative symptoms and examine additional...

Linda Steinholtz, Jonas Persson, E. Thörnblom et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.